Biotech · Private company
Iconic Therapeutics, Inc.
Track this companyFree. Adds Iconic Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- afliberceptPhase 2 · Choroidal NeovascularizationClinicalTrials.gov · fetched Nov 12, 2026
- hI-con1Phase 2 · Choroidal NeovascularizationClinicalTrials.gov · fetched Nov 12, 2026
- hI-con1™ 150µlPhase 2 · Neovascular Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- hI-con1™ 300µlPhase 2 · Neovascular Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- hI-con1™ 60µlPhase 2 · Neovascular Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ICON-1Phase 2 · Choroidal NeovascularizationClinicalTrials.gov · fetched Nov 12, 2026
- ranibizumabPhase 2 · Choroidal NeovascularizationClinicalTrials.gov · fetched Nov 12, 2026
- Sham injectionPhase 2 · Choroidal NeovascularizationClinicalTrials.gov · fetched Nov 12, 2026
- ICON-1Phase 1 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)PHASE2 · TERMINATED · started Mar 26, 2018ClinicalTrials.gov NCT03452527 · fetched Nov 12, 2026
- Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal MelanomaPHASE1 · COMPLETED · started May 1, 2016ClinicalTrials.gov NCT02771340 · fetched Nov 12, 2026
- Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular DegenerationPHASE2 · COMPLETED · started Feb 1, 2015ClinicalTrials.gov NCT02358889 · fetched Nov 12, 2026
- Safety and Tolerability Study for Age-Related Macular DegenerationPHASE1_PHASE2 · COMPLETED · started Dec 1, 2010ClinicalTrials.gov NCT01485588 · fetched Nov 12, 2026